Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with no effective treatments. Increasing evidence suggests that the epigenetic machinery in AD is perturbed and plays a significant role in the development and progression of the disease. Current research focuses on the mechanisms by which DNA methylation, histone modifications, and noncoding RNAs influence AD pathology. Implementing new drug targets is imperative because the existing ther-apeutic strategies for AD are neither cost-effective nor beneficial in decelerating disease progression. Here, we summarize the present understanding of the role of epigenetics in AD and provide insight into the prospective therapeutic interventions based on reversing these epigenetic modifications. There is also a discussion of the difficulties in translating these therapeutic options from the bench to the bedside.
| Original language | English |
|---|---|
| Title of host publication | Deciphering Drug Targets for Alzheimer’s Disease |
| Publisher | Springer Nature |
| Pages | 199-217 |
| Number of pages | 19 |
| ISBN (Electronic) | 9789819926572 |
| ISBN (Print) | 9789819926565 |
| DOIs | |
| Publication status | Published - 01-01-2023 |
All Science Journal Classification (ASJC) codes
- General Medicine
- General Neuroscience
- General Biochemistry,Genetics and Molecular Biology
- General Agricultural and Biological Sciences
Fingerprint
Dive into the research topics of 'Epigenetic Therapy for Alzheimer’s Disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver